항독소 시장(2026-2030년)

The global anti-venom market is forecasted to grow by USD 517.5 mn during 2025-2030, accelerating at a CAGR of 7.4% during the forecast period. The report on the global anti-venom market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing global incidence of envenomation and public health prioritization, technological innovations in antibody engineering and formulation stability, government funding, strategic stockpiling, and public procurement initiatives.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global anti-venom market is segmented as below:

By Type

• Polyvalent anti-venoms
• Monovalent anti-venoms
• Others

By Animal Type

• Snake
• Scorpion
• Spider
• Others

By End-User

• Hospitals
• Clinics
• ASCs

Geography

• North America
  • US
  • Canada
  • Mexico
• Asia
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the shift toward recombinant dna technologies and monoclonal antibody platforms as one of the prime reasons driving the global anti-venom market growth during the next few years. Also, expansion of regionalized biological manufacturing capabilities and domestic stockpiling and integration of cold-chain optimization technologies and field-stable formulations will lead to sizable demand in the market.

The report on the global anti-venom market covers the following areas:

• Global anti-venom market sizing
• Global anti-venom market forecast
• Global anti-venom market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global anti-venom market vendors that include Bharat Serums and Vaccines Ltd., BIOL S.A., Biological E. Ltd., BTG Specialty Pharmaceuticals, CSL Behring, Haffkine Bio Pharmaceutical, Incepta Pharmaceuticals Ltd., Inosan Biopharma S.L., Isera Biological Pvt. Ltd., Kamada Ltd., Laboratorios Bioclon S.A. de C.V., MicroPharm Ltd., Ophirex, Padra Serum Pvt. Ltd., Pfizer Inc., Premium Serums and Vaccines, Probiol S.A., Rare Disease Therapeutics Inc., Serum Institute of India Ltd., Silanes, VACSERA Holding Co., VETAL Animal Health Products Inc., VINS Bioproducts Ltd.. Also, the global anti-venom market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Animal Type
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Anti-Venom Market 2020 - 2024
  • Historic Market Size - Data Table on Global Anti-Venom Market 2020 - 2024 ($ million)
• 5.2 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
• 5.3 Animal Type segment analysis 2020 - 2024
  • Historic Market Size - Animal Type Segment 2020 - 2024 ($ million)
• 5.4 End-user segment analysis 2020 - 2024
  • Historic Market Size - End-user Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on global anti-venom market
• 6.2 Impact of geopolitical conflicts on global anti-venom market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Type

• 8.1 Market segments
• 8.2 Comparison by Type
• 8.3 Polyvalent anti-venoms - Market size and forecast 2025-2030
• 8.4 Monovalent anti-venoms - Market size and forecast 2025-2030
• 8.5 Others - Market size and forecast 2025-2030
• 8.6 Market opportunity by Type
  • Market opportunity by Type ($ million)

9 Market Segmentation by Animal Type

• 9.1 Market segments
• 9.2 Comparison by Animal Type
• 9.3 Snake - Market size and forecast 2025-2030
• 9.4 Scorpion - Market size and forecast 2025-2030
• 9.5 Spider - Market size and forecast 2025-2030
• 9.6 Others - Market size and forecast 2025-2030
• 9.7 Market opportunity by Animal Type
  • Market opportunity by Animal Type ($ million)

10 Market Segmentation by End-user

• 10.1 Market segments
• 10.2 Comparison by End-user
• 10.3 Hospitals - Market size and forecast 2025-2030
• 10.4 Clinics - Market size and forecast 2025-2030
• 10.5 ASCs - Market size and forecast 2025-2030
• 10.6 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Asia - Market size and forecast 2025-2030
  • 12.4.1 China - Market size and forecast 2025-2030
  • 12.4.2 India - Market size and forecast 2025-2030
  • 12.4.3 Japan - Market size and forecast 2025-2030
  • 12.4.4 South Korea - Market size and forecast 2025-2030
  • 12.4.5 Indonesia - Market size and forecast 2025-2030
  • 12.4.6 Thailand - Market size and forecast 2025-2030
• 12.5 Europe - Market size and forecast 2025-2030
  • 12.5.1 Germany - Market size and forecast 2025-2030
  • 12.5.2 UK - Market size and forecast 2025-2030
  • 12.5.3 France - Market size and forecast 2025-2030
  • 12.5.4 Italy - Market size and forecast 2025-2030
  • 12.5.5 Spain - Market size and forecast 2025-2030
  • 12.5.6 The Netherlands - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Turkey - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 Colombia - Market size and forecast 2025-2030
  • 12.6.7 South Africa - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Increasing global incidence of envenomation and public health prioritization
  • Technological innovations in antibody engineering and formulation stability
  • Government funding, strategic stockpiling, and public procurement initiatives
• 13.2 Market challenges
  • High production costs and intricate biological manufacturing workflows
  • Limited availability of venom sources and raw materials
  • High risk of adverse immunological reactions and complex regulatory approvals
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Shift toward recombinant DNA technologies and monoclonal antibody platforms
  • Expansion of regionalized biological manufacturing capabilities and domestic stockpiling
  • Integration of cold-chain optimization technologies and field-stable formulations

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Bharat Serums and Vaccines Ltd.
  • Bharat Serums and Vaccines Ltd. - Overview
  • Bharat Serums and Vaccines Ltd. - Product / Service
  • Bharat Serums and Vaccines Ltd. - Key offerings
  • SWOT
• 15.5 BIOL S.A.
  • BIOL S.A. - Overview
  • BIOL S.A. - Product / Service
  • BIOL S.A. - Key offerings
  • SWOT
• 15.6 Biological E. Ltd.
  • Biological E. Ltd. - Overview
  • Biological E. Ltd. - Product / Service
  • Biological E. Ltd. - Key offerings
  • SWOT
• 15.7 CSL Behring
  • CSL Behring - Overview
  • CSL Behring - Product / Service
  • CSL Behring - Key offerings
  • SWOT
• 15.8 Incepta Pharmaceuticals Ltd.
  • Incepta Pharmaceuticals Ltd. - Overview
  • Incepta Pharmaceuticals Ltd. - Product / Service
  • Incepta Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 15.9 Inosan Biopharma S.L.
  • Inosan Biopharma S.L. - Overview
  • Inosan Biopharma S.L. - Product / Service
  • Inosan Biopharma S.L. - Key offerings
  • SWOT
• 15.10 Isera Biological Pvt. Ltd.
  • Isera Biological Pvt. Ltd. - Overview
  • Isera Biological Pvt. Ltd. - Product / Service
  • Isera Biological Pvt. Ltd. - Key offerings
  • SWOT
• 15.11 Kamada Ltd.
  • Kamada Ltd. - Overview
  • Kamada Ltd. - Business segments
  • Kamada Ltd. - Key offerings
  • Kamada Ltd. - Segment focus
  • SWOT
• 15.12 Laboratorios Bioclon S.A. de C.V.
  • Laboratorios Bioclon S.A. de C.V. - Overview
  • Laboratorios Bioclon S.A. de C.V. - Product / Service
  • Laboratorios Bioclon S.A. de C.V. - Key offerings
  • SWOT
• 15.13 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.14 Premium Serums and Vaccines
  • Premium Serums and Vaccines - Overview
  • Premium Serums and Vaccines - Product / Service
  • Premium Serums and Vaccines - Key offerings
  • SWOT
• 15.15 Probiol S.A.
  • Probiol S.A. - Overview
  • Probiol S.A. - Product / Service
  • Probiol S.A. - Key offerings
  • SWOT
• 15.16 Rare Disease Therapeutics Inc.
  • Rare Disease Therapeutics Inc. - Overview
  • Rare Disease Therapeutics Inc. - Product / Service
  • Rare Disease Therapeutics Inc. - Key offerings
  • SWOT
• 15.17 Serum Institute of India Ltd.
  • Serum Institute of India Ltd. - Overview
  • Serum Institute of India Ltd. - Product / Service
  • Serum Institute of India Ltd. - Key offerings
  • SWOT
• 15.18 VACSERA Holding Co.
  • VACSERA Holding Co. - Overview
  • VACSERA Holding Co. - Product / Service
  • VACSERA Holding Co. - Key offerings
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations